Filing Details

Accession Number:
0001415889-23-006838
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-04-25 18:00:08
Reporting Period:
2023-04-21
Accepted Time:
2023-04-25 18:00:08
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1798749 Aerovate Therapeutics Inc. AVTE Pharmaceutical Preparations (2834) 831377888
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1868997 Hunter Gillies C/O Aerovate Therapeutics, Inc.
930 Winter Street, Suite M-500
Waltham MA 02451
Chief Medical Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-04-21 4,000 $1.74 5,960 No 4 M Direct
Common Stock Disposition 2023-04-21 4,000 $19.50 1,960 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2023-04-21 4,000 $0.00 4,000 $1.74
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
20,108 2030-09-03 No 4 M Direct
Footnotes
  1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023.
  2. A total of 24,108 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.